Article Information
History
- March 23, 2022.
Article Versions
- Version 1 (October 14, 2021 - 18:49).
- Version 2 (March 22, 2022 - 13:24).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Noelia Diaz Troyano1,*,
- Pablo Gabriel Medina1,*,
- Stephen Weber2,#,
- Martin Klammer2,
- Raquel Barquin-DelPino1,
- Laura Castillo-Ribelles1,
- Angels Esteban1,
- Manuel Hernández-González1,
- Roser Ferrer-Costa1,
- Tomas Pumarola1 and
- Francisco Rodriguez Frias1,3,#
- 1Clinical Biochemistry (Clinical Laboratories), Vall d’Hebron University Hospital, Barcelona, Spain
- 2Roche Diagnostics GmbH, Penzberg, Germany
- 3Vall d’Hebron Research Institut, Barcelona, Spain
- ↵#Joint corresponding authors:
Francisco Rodriguez Frias and Stephen Weber, (frarodri{at}vhebron.net), (stephen.weber{at}roche.com)
Posted March 23, 2022.
Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2
